Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis

Proc Soc Exp Biol Med. 1989 May;191(1):1-4. doi: 10.3181/00379727-191-42880.

Abstract

We measured mitogenic activity of whole blood serum and platelet-poor plasma-derived serum of a group of 10 patients with progressive systemic sclerosis and of 8 controls. Mitogenic activity of plasma-derived serum was greater in patients than in controls, in the absence of other signs of platelet activation. This increased activity was inhibited by specific antibodies, anti-platelet derived growth factor, suggesting that circulating levels of platelet-derived growth factor may be present in progressive systemic sclerosis patients. Platelet-derived growth factor, released either by platelets or by monocytes, might play a role in the pathogenesis of scleroderma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Assay
  • Cell Line
  • DNA / biosynthesis
  • Humans
  • Immunoassay
  • Platelet-Derived Growth Factor / blood*
  • Platelet-Derived Growth Factor / pharmacology
  • Scleroderma, Systemic / blood*

Substances

  • Platelet-Derived Growth Factor
  • DNA